Bredlau Amy Lee, Korones David N
Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina, USA; Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina, USA.
Department of Pediatrics, University of Rochester, Rochester, New York, USA; Department of Palliative Care, University of Rochester, Rochester, New York, USA.
Adv Cancer Res. 2014;121:235-259. doi: 10.1016/B978-0-12-800249-0.00006-8.
Diffuse intrinsic pontine gliomas (DIPGs) are a fairly common pediatric brain tumor, and children with these tumors have a dismal prognosis. They generally are diagnosed within the first decade of life, and due to their location within the pons, these tumors are not surgically resectable. The median survival for children with DIPGs is less than 1 year, in spite of decades of clinical trial development of unique approaches to radiation therapy and chemotherapy. Novel therapies are under investigation for these deadly tumors. As clinicians and researchers make a concerted effort to obtain tumor tissue, the molecular signals of these tumors are being investigated in an attempt to uncover targetable therapies for DIPGs. In addition, direct application of chemotherapies into the tumor (convection-enhanced delivery) is being investigated as a novel delivery system for treatment of DIPGs. Overall, DIPGs require creative thinking and a disciplined approach for development of a therapy that can improve the prognosis for these unfortunate children.
弥漫性脑桥内生型胶质瘤（DIPG）是一种相当常见的儿童脑肿瘤，患有这些肿瘤的儿童预后很差。它们通常在生命的第一个十年内被诊断出来，并且由于其位于脑桥内，这些肿瘤无法通过手术切除。尽管数十年来针对放射治疗和化疗的独特方法进行了临床试验开发，但患有DIPG的儿童的中位生存期仍不到1年。针对这些致命肿瘤的新型疗法正在研究中。随着临床医生和研究人员齐心协力获取肿瘤组织，这些肿瘤的分子信号正在被研究，试图找到针对DIPG的可靶向治疗方法。此外，将化疗药物直接注入肿瘤（对流增强递送）作为一种治疗DIPG的新型递送系统正在被研究。总体而言，DIPG需要创造性思维和严谨的方法来开发一种能够改善这些不幸儿童预后的疗法。
Zotero 插件